NCI-supported cancer trials approaching "state of crisis", says IOM report
This article was originally published in Scrip
A recent report by the US Institute of Medicine (IOM) has found that the system for conducting US-government supported cancer clinical trials is approaching a state of crisis, and it recommends that urgent changes be made to the US National Cancer Institute (NCI)-supported Clinical Trials Cooperative Group Program.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.